“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Correlations Between Patient-Reported Outcomes and Clinical Responses in the Phase 3 Clinical Trials POETYK PSO-1 and POETYK PSO-2”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 6, Nov. 2022, p. s63, https://doi.org/10.25251/skin.6.supp.63.